**Manuscript title**

Hypertension management in cardio-oncology

Hani Essa1, Gregory Y. H. Lip1,2

1 Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool Heart & Chest Hospital, Liverpool, UK

2 Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

**Author Contact information**

Gregory Y. H. Lip, MD, Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK

Email: gregory.lip@liverpool.ac.uk

Tel +44 151 794 9020

Hani Essa, MRCP, Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK

Email: Hani\_essa@hotmail.com

**Corresponding Author**

Prof Gregory Y. H. Lip, MD, Email: gregory.lip@liverpool.ac.uk

**Disclosure statement**

Dr Essa has nothing to declare. Professor Lip reports consultancy and speaker fees from Bayer, Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife, Roche, and Daiichi-Sankyo outside the submitted work. No fees received personally

**Word count excluding tables/figures/abstract/references** – 3111

**Keywords** – Hypertension, Cardio-oncology, VEGF, oncology, cardiology

**Abbreviations as they appear in the text:** US, United States; CVD, Cardiovascular disease; ESC, European Society of Cardiology; BP, Blood pressure, VEGF, Vascular Endothelial growth factor; TKI, tyrosine kinase inhibitor; NO, Nitric oxide, CCB, calcium channel blocker; ARB, Angiotensin receptor blocker.

**Abstract**

Cancer is one of the leading causes of death worldwide. During the last few decades prognosis has improved dramatically and patients are living longer and suffering long term cardiovascular stigmata of chemotherapeutic agents. Cardiovascular disease is the leading cause of morbidity and mortality in cancer survivors second only to recurrent cancer. This has led to a new field of medicine coined cardio-oncology to manage this subset of the population. Hypertension is arguably the single most common cardiovascular disease seen in this cohort. The aetiology of hypertension in cardio-oncology is complex and multifactorial based on the type of chemotherapy, type of malignancy and intrinsic patient factors such as age and pre-existing comorbidities. A variety of different oncological treatments have been implicated in causing hypertension. The effect can be transient whilst undergoing treatment or can be delayed occurring decades after treatment. A tailored management plan is recommended given the plethora of agents and their differing underlying mechanisms and speed of this mechanism in causing hypertension. Management by a multidisciplinary team consisting of oncology, family medicine and cardiology is advised. There are currently no trials comparing antihypertensives in this specific cohort of patients. In the absence of evidence demonstrating otherwise, hypertension in cardio-oncology should be managed utilising the same treatment guidelines for the general population.

1. **Introduction**

Cancer is one of the leading causes of death worldwide. In the United States (US) cancer is the second most common cause of death with an expected toll of 606,520 in 2020. Advances in oncological treatment have led to improved survival of patients with a year on year decline in mortality between 1991 and 2017 in the US1. The increase in cancer survivors has been accompanied by increasing cardiovascular disease (CVD) morbidity and mortality due to downstream side-effects of treatment. The overall societal burden of CVD in oncology is likely to increase with an increasing aging population and an overall lifetime risk of nearly 40% of developing cancer in the US1.

Cardio-oncology is a relatively new clinical field focusing on the diagnosis, prevention, and treatment of the cardiovascular stigmata of cancer and its treatments. Approximately 75% of cancer survivors have chronic health problems. CVD is the leading cause of morbidity and mortality in this population second only to recurrent malignancy. The risk of CVD in cancer survivors is 800% higher than that of the general population. The relative risk of coronary artery disease and heart failure is over 1000% more in cancer survivors as compared to their cancer free sibling2. **Cancer treatments in general share various detrimental effects in common, especially upregulation of cardiovascular risk factors3. This can lead to both short- and long-term cardiovascular complications. The increasing recognition of this resulted in the building of the** world’s first cardio-oncology unit in the MD Anderson Center in the US in 2000. Following this, the international cardio-oncology society was born in 20094**.**

**Although the field of cardio-oncology has received increasing attention in recent years, many aspects of both radiation-induced and cancer drug–induced CVD are still to be fully elucidated.** As the field advances, insights into mechanisms of cardiovascular toxicities and hypertension have become more evident. There are currently 9 main CVD stigmata of cancer treatments, these are (Figure 1):

* Heart failure
* Pulmonary hypertension
* Valvular disease
* Cardiac arrythmias
* Thromboembolic disease
* Peripheral vascular disease
* Stroke
* Coronary artery disease
* Pericardial disease

Essential hypertension is a leading cause of morbidity and mortality worldwide. The relationship between blood pressure (BP) and CVD is continuous, but for the sake of pragmatism hypertension is defined by the European Society of Cardiology (ESC) as a BP ≥ 140/90 5. The overall prevalence of hypertension in adults is around 30 − 45% and this increases with increasing age, with a prevalence of >60% in people aged >60 years6.

Hypertension has been reported to be the most common comorbidity in cancer patients7. Hypertension is a well-recognised cause of CVD morbidity and mortality and is implicated in strokes, coronary heart disease, peripheral arterial disease, heart failure and renal disease.

The relationship between hypertension and cancer is multi-faceted. Hypertension, CVD, and chronic kidney disease share several common risk factors including smoking, increasing age, diabetes mellitus and obesity. In cancer patients, the aetiology of hypertension is influenced by the type of chemotherapy, radiation therapy, and by the malignancy itself. The prevalence of hypertension in patients is therefore difficult to estimate given the heterogeneity present. However, retrospective data in patients without a prior diagnosis of hypertension have demonstrated that around 33% of patients will develop hypertension 8. This is particularly more profound in patients treated with angiogenesis inhibitors, where rates of hypertension close to 70% have been reported with some therapies9.

Table 1 grades the severity of hypertension occurring secondary to anti-cancer therapies based on the latest version of US Common Terminology Criteria for Adverse Events10. This rating system categorizes “any unfavorable symptom, sign, or disease associated with the use of a medical treatment or procedure that may or may not be considered related to or caused by the medical treatment or procedure”. This rating system is often utilised in analysis of hypertension secondary to oncology treatement.

The focus of this article is to review the literature with regards to the development and management of hypertension in cardio-oncology. Specifically, the scope of this article will focus on hypertension as a stigmata of cancer therapy rather than hypertension induced by cancer.

**2. Aetiology of hypertension in relation to oncology treatments**

**2.1 Angiogenesis inhibitors**

Angiogenesis is an essential process in the natural course of cancer, as it mediates tumour growth and metastasis. Angiogenesis inhibitors generally exert their effect via inhibition of a component of the vascular endothelial growth factor (VEGF) signalling pathway via two main mechanisms. The first directly inhibit VEGF ligand’s ability to bind to its target receptor and includes bevacizumab and ramucirumab. These medications are classified as VEGF inhibitors. The second class inhibit tyrosine kinases which would be activated by the VEGF ligand-receptor interactions and includes agents such as sunitinib & sorafenib. These medications are classified as tyrosine kinase inhibitors (TKI).

Angiogenesis inhibitors are a well-recognised cause of CVD including hypertension. All commercially available angiogenesis inhibitors have been implicated in the development of hypertension to varying degrees11. VEGF signalling inhibitor induced elevation in blood pressure appears to be not an adverse event of the therapy, but rather a mechanism-dependent on-target toxicity12. In a metanalysis of 77 studies of 11 different angiogenesis inhibitors and 30,593 patients the likelihood of new hypertension had an odds ratio of 5.28 (95% Confidence interval of 4.53 – 6.15)13. Table 3 demonstrates the prevalence of hypertension with a variety of different angiogenesis inhibitors are reported in meta-analysis’.

Drug-related hypertension may occur from initiation of therapy to up to a year after treatment onset14. The incidence of hypertension seems to depend on multiple variables, such as type of drug, dose and schedule utilised. Patient characteristics further play a part with those with pre-existing hypertension at greater risk, along with the elderly (age > 60 years) and more obese patients (body mass index ≥ 25)15. There is some evidence that severity is dose dependent and appears to be transient with normal BP values restored after discontinuation16.

The pathophysiology of new or worsening hypertension is unclear; but is likely to be multifactorial with multiple biologically plausible theories hypothesized. There is evidence that VEGF activation induces the expression of nitric oxide synthase in endothelial cells, which promotes vasodilation; the inhibition of this pathway thus suppresses the nitric oxide pathway and induces hypertension via vasoconstriction. Furthermore, there is evidence in increasing levels of endothelin-1, the most potent vasoconstrictor known, which further contributes. Plasma endothelin-1 levels are elevated two- to three-fold in patients treated with VEGF inhibitors17. This appears to be dose-dependent and may explain the dose-dependent rise in BP18. Additionally, VEGF is expressed in endothelial cells and in the kidneys and is known to play an important role in cellular proliferation and homeostasis in both sites. It has also been shown that there is parallel losses of capillary circulation in both tumour and nontumor tissue. It is thought that these factors, in combination with systemic thrombotic microangiopathy contribute to the resulting development of hypertension19.

**2.2 Mitotic inhibitors**

Mitotic inhibitors inhibit mitosis via disruption of microtubules. Vinca alkaloids such as vincristine have been suggested to cause hypertension20. These mechanism for this is unclear and the strength of the association is confounded by the fact that these agents are often utilised in combination with other drugs 21. There is some evidence that vinca alkaloids result in mitosis mediated inhibition of endothelial cell proliferation and endothelial cell caspase mediated apoptosis. It is unclear if this contributes to hypertension22.

**2.3 Antimetabolite therapy**

Antimetabolite therapy interfere with deoxyribonucleic acid production and inhibit cell division. There is some evidence to suggest that Gemcitabine can induce hypertension in the context of thrombotic microangiopathy23. Reports from a case series of 29 patients also demonstrate that gemcitabine induced or worsened hypertension in 26 of them likely secondary to nephrotoxicity24.

**2.4 Alkylating and alkylating-like agents**

Alkylating agents stops the proliferation of neoplasia via attaching an alkyl group to DNA causing subsequent damage. Alkylating-like agents act similarly to alkylating agents; however, they lack the alkyl group. These agents were historically and originally utilised as mustard gas during the second world war. However, alkylating agents such as cyclophosphamide, chlorambucil and busulfan and alkylating-like agents such as cisplatin have since found widespread medical utility and represent the oldest class of anti-cancer medications. In a case series of multiple alkylating agents, 15/18 patients developed new hypertension 25. The mechanism(s) for this is unclear. Alkylating-like agents have been implicated in causing hypertension which is thought to be secondary to underlying nephrotoxicity 26. Cisplatin treatment has been correlated with a dose-dependent increase in hypertension in testicular cancer survivors27.

**2.5 Anthracyclines**

Anthracyclines such as doxorubicin and daunorubicin work by interfering with DNA metabolism. The dose-dependent left ventricular dysfunction effects of anthracyclines are well recognised. It is however less clear if they cause hypertension. There is evidence that hypertension has a synergistic effect with anthracycline-induced cardiotoxicity, producing substantially higher risks of heart failure28. These findings that pre-existing hypertension predispose to higher rates of heart failure following treatment with anthracyclines have been seen in multiple other studies29, 30. This raises the importance of appropriate management of hypertension in this cohort of patients.

**2.6 Calcineurin inhibitors**

Calcineurin inhibitors are potent immunosuppressive drugs which can be utilised in oncology often as adjuvant therapy. Calcineurin is a calcium- and calmodulin-dependent serine-threonine phosphatase important for function of T-helper cells31. Examples include cyclosporin and tacrolimus. These have been linked to hypertension by a multifactorial combination of renal artery vasoconstriction32 and activation of the renin-angiotensin system33.

**2.7 Proteasome inhibitors**

Proteasome inhibition may prevent degradation of pro-apoptotic factors such as the p53 protein, permitting activation of programmed cell death in neoplastic cells dependent upon suppression of pro-apoptotic pathways34. Examples include Carfilzomib and Bortezomib. A 2014 retrospective analysis of 2509 patients treated with bortezomib were noted to have a non-significant trend towards hypertension compared to those not treated with bortezomib35. It is possible that this mechanism of hypertension is mediated via diminished NO bioavailability and subsequent vasoconstriction36.

**2.8 Radiotherapy**

There is some evidence that demonstrates that radiotherapy to the head and neck can result in hypertension37. However, there is also evidence to suggest that radiotherapy for head and neck cancers results in a permanent reduction in blood pressure38. It is likely the mechanism for both hypertension and hypotension is baroceptor failure. The mechanism responsible for hypertension in survivors of testicular cancer following radiotherapy is however less clear27. The pattern of hypertension post radiotherapy is also seen in those undergoing thorax and abdominal radiation39.

**2.9 Steroids**

Steroid therapy is utilised in a variety of chemotherapy regimens and for treating symptoms of cancer. It has long been recognised that steroids induce hypertension and that this is dose dependent40. Mineralocorticoid hypertension is thought to be mainly secondary to sodium retention, whilst glucocorticoid hypertension is believed to result from altered vascular reactivity40.

1. **Diagnosis**

Hypertension is predominantly an asymptomatic condition that is best detected by frequent and careful screening of at-risk groups such as cancer patients. Some chemotherapeutic agents cause hypertension in the first few cycles and others are more likely to cause hypertension 10 years after diagnosis. Personalised management is recommended given the plethora of agents and their differing underlying mechanisms and speed of this mechanism in causing hypertension. Therefore, cancer patients require both frequent and early assessment and a long-term approach. Patients undergoing chemotherapy warrant close monitoring of their BP throughout the course of treatment. This can be done via weekly visits to a nurse’s office or via home monitoring following patient education.

The diagnosis of hypertension is based on a persistent BP ≥ 140/90. The BP should be checked in both arms (unless contraindicated by lymphedema or other impairments). In cancer patients it is important to assess for the presence of temporary interfering substances that could be causative in a persistently elevated BP such as pain and high dose steroids. It is recommended to utilise ambulatory BP monitoring over a 3-6-day period as a means of diagnosis rather than spot testing to avoid over-diagnosis of “white coat” hypertension. Ambulatory monitoring is typically performed every 15 to 30 minutes during the day and every 30 to 60 minutes at night. Diagnosis via ambulatory monitoring is the gold standard due to a stronger association with cardiovascular outcomes, reflecting the hypertension ‘load’ over the 24 hours. The diagnostic threshold in ambulatory monitoring is often lowered to an average BP ≥ 135/85 41.

1. **Management**

Effectively lowering BP reduces morbidity and mortality from congestive heart failure, myocardial infarction, stroke, and renal insufficiency. The risk of these adverse outcomes is proportional to the level and duration of the BP42. A multi-disciplinary team is required as the aetiology of hypertension is complex and can arise before/during/after treatment. Treatment is often best guided by a combination of physicians in oncology, cardiology and primary care. Traditional recommendations regarding lifestyle changes including physical exercise, weight reduction, dietary change and sodium restriction, though potentially beneficial and advisable, may be unachievable in the clinical setting of advanced malignancy. Therefore, pharmacological therapy tends to dominate.

In keeping with the complex aetiology there is no universal approach to pharmacological choices. In contrast to normal management of hypertension where the primary goal is to prevent long term stigmata of elevated BP. In cardio-oncology patients life expectancy can be much more limited and therefore, the goals of treatment tend to differ depending on this context. Treatment remains important to prevent acute complications of hypertension even in patients with limited prognoses. An individualised treatment approach is advised if there is evidence of an underlying aetiology and treatment should take note of patient’s comorbid conditions such as chronic kidney disease, diabetes, and heart failure.

All patients should undergo a formal evaluation and documentation of pre-treatment risk for cardiovascular disease. Blood pressure values and proteinuria should be assessed before initiation of treatment, and if hypertension is present antihypertensive treatment should be started first. The purpose of this assessment is to identify patients at high risk for chemotherapy induced hypertension, especially if VEGF inhibitors are being considered. There is evidence demonstrating that pre-existing hypertension in cancer patients confers worse prognosis with increasing mortality43. The main goal of treatment is to reduce blood pressure to less than 140/90. This target is based on existing guidelines for the treatment of hypertension in all patients5, 44. There are no individualised targets for oncology patients per se.

In higher risk patients, particularly those with diabetes or chronic kidney disease, stricter targets should be utilised aiming for 130/80. In patients already taking anti-hypertensive medication adherence to treatment should be initially verified and compliance ensured. In patient’s adherent to medication whose blood pressure is still above their target range, medications should be titrated up to the maximal tolerated dose prior to introduction of a second agent. Hypertension should not preclude initiation of chemotherapy unless the risk of hypertension is deemed too high by the treating physician. No studies have compared the efficacy of different antihypertensive agents in treating chemotherapy induced hypertension. Therefore, in the absence of evidence to say otherwise, the ACE inhibitors, ARBs and non-dihydropyridine calcium channel blockers (CCB) are all considered viable first line therapy. Diuretics may be used, but some caution is advised as they may cause electrolyte depletion and consequent QT prolongation. This may be worsened in the setting of chemotherapy agents that commonly cause diarrhoea and potential dehydration.

**4.1 Hypertension during VEGF treatment**

New hypertension during treatment with VEGF inhibitors is so prevalent that this topic warrants its own discussion regarding its management. Figure 2 demonstrates an algorithm for BP management during treatment with VEGF inhibitors. In this cohort it recognised that the majority of increase in blood pressure occurs during the first cycle45. Treatment should be initiated when hypertension develops, or diastolic BP increases by 20mmhg. This is based on expert recommendations by the Cardiovascular Toxicities Panel of the National Cancer Institute46. There are conflicting data in the literature regarding which class of medications is more effective in reduction on BP. Currently there is no formal evidence to suggest any agent is more efficacious and therefore none is currently recommended over another. The main recommendation is to avoid non-dihydropyridine calcium channel blockers (CCBs). This is based on the fact that non-dihydropyridine CCBs inhibit cytochrome P450 3A4, the enzyme that metabolizes VEGF inhibitors, leading to potentially high VEGF inhibitor plasma levels, which may aggravate VEGF inhibitor-induced hypertension47. Temporary cessation of VEGF inhibitors has been demonstrated to be useful when hypertension is proving difficult to control with normal agents48. In general, the hypertensive effect of VEGF inhibitors dissipates after cessation of the agent. This necessitates monitoring of BP following completion of a treatment course with withdrawal of anti-hypertensive medications when BP returns to baseline. In general, prognosis is good, treatment induced hypertension secondary to angiogenesis inhibitors is commonly low-grade, and easily correctable with standard antihypertensive medications.

Hypertension in the context of angiogenesis inhibitors has even been suggested as a possible biomarker of clinical efficacy. A retrospective analysis of nearly 5000 patients with renal cell carcinoma demonstrated that treatment associated hypertension with sunitinib was significantly and independently associated with improved clinical outcomes. Furthermore, that the utilisation of antihypertensives to control high BP has no effect on the treatment outcome, suggesting that there is no contraindication to managing hypertension properly in patients treated with angiogenesis inhibitors49.

Several treatments have been proposed based on the pathophysiology of hypertension in patients treated with angiogenesis inhibitors. This includes endothelin-1 receptor blockers, increasing NO bioavailability and salt restriction. To date there have been no trials with enothelin-1 receptor blockers. There have been case reports on the efficacy of NO donors for the treatment of VEGF-induced hypertension50. There is also one trial looking at the value of a low salt (<4g/day) diet on the VEGF-induced hypertension due to finish on in 2020 ((Dutch trial register NTR7556)

**Conclusion**

Hypertension, and CVD are common in patients undergoing treatment for cancer. This likely contributes to increasing CVD morbidity and mortality as compared to the general population. The estimated prevalence of hypertension in cancer patients is expected to increase as the prognosis of cancer improves and more patients survive to experience long term stigmata of chemotherapy. All cancer patients should undergo a pre-chemotherapy risk assessment to identify and appropriately manage hypertension. These patients should be monitored closely during their chemotherapy (especially if angiogenesis inhibitors are utilised) and post treatment for the development of hypertension.

There is a paucity of data in the literature with regards to the management of hypertension in cardio-oncology. High quality trials are required to generate evidence-based guidance for clinicians on the best management strategies in this population. In the absence of evidence to say otherwise, hypertension in cardio-oncology should be treated utilising the same medications used in the general population. Key areas to investigate would be randomized treatment trials in patients with hypertension post chemotherapy to create evidenced based treatment plans & the data studies looking at the effect of reducing hypertension in preventing cardiovascular events in cancer patients.

.




Figure 1. Cancer treatment and its stigmata on the cardiovascular system

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Grade | 1 | 2 | 3 | 4 | 5 |
| Description for hypertension | Systolic BP 120 -139 mm Hg or diastolic BP 80 - 89 mm Hg | Systolic BP 140 -159 mm Hg or diastolic BP 90 - 99 mm Hg if previously within normal limits; change in baseline medical intervention indicated; recurrent or persistent (>=24 hrs); symptomatic increase by >20 mm Hg (diastolic) or to >140/90 mm Hg; monotherapy indicated initiated | Systolic BP >=160 mm Hg or diastolic BP >=100 mm Hg; medical intervention indicated; more than one drug or more intensive therapy than previously used indicated | Life-threatening consequences (e.g., malignant hypertension, transient or permanent neurologic deficit, hypertensive crisis); urgent intervention indicated | Death |
| **Table 1 – Classification of the severity of hypertension occurring secondary to anti-cancer therapies in adults based on the latest version of US Common Terminology Criteria for Adverse Events10.** | | | | | |

|  |  |
| --- | --- |
| Chemotherapy agent | Proposed mechanisms of action |
| Vascular endothelial growth factor inhibitors   * Bevacizumab * Ramucirumab * Sunitinib * Sorafenib | * Suppression of the nitric oxide pathway and vasodilation19 * Increasing endothelin-1 and vasoconstriction, vascular remodelling19 * Systemic thrombotic microangiopathy and oxidative stress19 |
| Mitotic inhibitors   * Vincristine | * Mitosis mediated inhibition of endothelial cell proliferation22 * Endothelial cell caspase mediated apoptosis |
| Antimetabolite agents   * Gemcitabine | * Thrombotic microangiopathy23 |
| Alkylating agents   * Cyclophosphamide * Chlorambucil * Busulfan | * Renal toxicity and microalbuminemia51 * Disruption of endothelial function52 |
| Calcineurin inhibitors   * Cyclosporin * tacrolimus | * Renal artery vasoconstriction32 * Activation of the renin-angiotensin system33 * Sodium retention53 |
| Proteasome inhibitors   * Carfilzomib | * Thrombotic microangiopathy36 * Reduction in nitric oxide and subsequent vasoconstriction36 |
| Steroids   * Dexamethasone | * Sodium retention40 * altered vascular reactivity40 |
| Head and neck radiation | * Baroceptor failure37 |
| **Table 2. Treatments utilised in cancer treatment and possible mechanisms for resultant hypertension.** | |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Agent | Type | Incidence of hypertension | 95% confidence interval | Relative Risk (RR) | 95% confidence interval | Number of patients | Number of trials |
| Bevacizumab54 | IgG1 | 23.6% | 20.5–27.1 | 3.02 | 2.24–4.07 | 6754 | 20 |
| Sunitinib55 | TKI | 21.6% | 18.7-24.8 | 3.44 | 0.62-19.15 | 4999 | 13 |
| Pazopanib56 | TKI | 35.9% | 31.5-40.6 | 4.97 | 3.38-7.30 | 1651 | 13 |
| Sorafenib57 | TKI | 23.1% | 19.3–26.9 | 3.06 | 2.04–4.59 | 4878 | 13 |
| Aflibercept58 | Fusion protein | 42.4% | 35.0-50.3 | 4.47 | 3.84–5.22 | 4451 | 15 |
| Axitinib59 | TKI | 40.1% | 30.9-50.2 | 3.00 | 1.29-6.97 | 1908 | 10 |
| Vandetanib60 | TKI | 24.2% | 18.1-30.2 | 5.10 | 3.76-6.92 | 3154 | 11 |
| Regorafenib61 | TKI | 44.4% | 30.8-59.0 | 3.76 | 2.35-5.99 | 750 | 5 |
| Ramucirumab | IgG1 | 20.0% | 15.0-26. | 2.77 | 1.94-3.94 | 3851 | 11 |
| **Table 3 – Incidence of hypertension with various angiogenesis inhibitor medications. TKI; Tyrosine kinase inhibitor** | | | | | | | |




Figure 2. Proposed treatment algorithm for patients starting on angiogenesis inhibitors. ACEi, Ace inhibitor; ARB, Angiotensin receptor blocker; CCB, calcium channel blocker; VEGF, Vascular endothelial growth factor

``

`

**References**

1. RL S, KD M, A J. Cancer Statistics, 2020. CA: a cancer journal for clinicians 2020 2020 Jan;70(1).

2. Akam-Venkata J, Franco VI, Lipshultz SE. Late Cardiotoxicity: Issues for Childhood Cancer Survivors. Curr Treat Options Cardiovasc Med 2016 Jul;18(7):47.

3. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 2015 Sep;12(9):547-58.

4. Lenihan DJ, Cardinale D, Cipolla CM. The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis 2010 Sep-Oct;53(2):88-93.

5. B W, G M, W S, E AR, M A, M B, et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of hypertension 2018 2018 Oct;36(10).

6. CK C, KK T, S R, S I, R G, A A, et al. Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries. JAMA 2013 09/04/2013;310(9).

7. JF P, RM T, I C, L G, EL S. Prognostic Importance of Comorbidity in a Hospital-Based Cancer Registry. JAMA 2004 05/26/2004;291(20).

8. Fraeman KH, Nordstrom BL, Luo W, Landis SH, Shantakumar S. Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study. Int J Hypertens 2013;2013.

9. M S, M T, LJ W, B R, MS B, R E, et al. Lenvatinib Versus Placebo in Radioiodine-Refractory Thyroid Cancer. The New England journal of medicine 2015 02/12/2015;372(7).

10. Common Terminology Criteria for Adverse Events (CTCAE) - CTCAE\_v5\_Quick\_Reference\_8.5x11.pdf. 2020 [cited 09/06/2020]; Version 5:[Available from: <https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf>

11. El-Kenawi AE, El-Remessy AB. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol 2013 Oct;170(4):712-29.

12. M S, A E. "On-target" Cardiac Effects of Anticancer Drugs: Lessons From New Biology. Journal of the American College of Cardiology 2012 08/14/2012;60(7).

13. H A-Q, JL E, DS L, P T, E A. Cardiovascular Toxicity of Angiogenesis Inhibitors in Treatment of Malignancy: A Systematic Review and Meta-Analysis. Cancer treatment reviews 2017 2017 Feb;53.

14. CP E, A Z. Vascular Endothelial Growth Factor Inhibitor-Induced Hypertension: Basics for Primary Care Providers. Cardiology research and practice 2011 2011;2011.

15. OP H, TK C, A T, RR M, L G, M D, et al. Clinical Risk Factors for the Development of Hypertension in Patients Treated With Inhibitors of the VEGF Signaling Pathway. Cancer 2015 01/15/2015;121(2).

16. BR C, C B, J S, S W, K B. Bevacizumab Induced Hypertension in Gynecologic Cancer: Does It Resolve After Completion of Therapy? Gynecologic oncology reports 2016 06/16/2016;17.

17. MH K, JH vE, W S, S S, AH D, AH vdM. Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating endothelin-1 Levels. Hypertension (Dallas, Tex : 1979) 2010 2010 Oct;56(4).

18. S L, HJ B, MH K, FM S, A H, MC C-vG, et al. Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With Sunitinib. Hypertension (Dallas, Tex : 1979) 2015 2015 Sep;66(3).

19. Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension Induced by VEGF Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker. Semin Nephrol 2010 Nov;30(6):591-601.

20. C B, CC B, MA K, HJ S. Evaluation of Long-Term Toxicity After Chemotherapy for Testicular Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996 1996 Nov;14(11).

21. G S, A K, CP V, A S, DT S, PH W, et al. Ten-year Survival and Late Sequelae in Testicular Cancer Patients Treated With Cisplatin, Vinblastine, and Bleomycin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989 1989 Aug;7(8).

22. A S, G M, C A, G P, D P, MA D, et al. Endothelial Vascular Toxicity From Chemotherapeutic Agents: Preclinical Evidence and Clinical Implications. Cancer treatment reviews 2012 2012 Aug;38(5).

23. H I, C I-B, V L-V, L M, I T, O R, et al. Gemcitabine-induced Thrombotic Microangiopathy: A Systematic Review. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2006 2006 Nov;21(11).

24. I G, MG K, V M, S S, CD F. Gemcitabine Nephrotoxicity and Hemolytic Uremic Syndrome: Report of 29 Cases From a Single Institution. Clinical nephrology 2009 2009 Feb;71(2).

25. SW G, JP E, SM S, K S, A B, KH A, et al. Endogenous Digoxin-Like Immunoreactive Factor and Digitalis-Like Factor Associated With the Hypertension of Patients Receiving Multiple Alkylating Agents as Part of Autologous Bone Marrow Transplantation. Clinical science (London, England : 1979) 1989 1989 Nov;77(5).

26. EC K, A B, NS T, JM T, E vD-dB, HJ vdP, et al. Early and Late Adverse Renal Effects After Potentially Nephrotoxic Treatment for Childhood Cancer. The Cochrane database of systematic reviews 2019 03/11/2019;3(3).

27. H S, N A, SD F, O D, O K, EA W, et al. Blood Pressure and Body Mass Index in Long-Term Survivors of Testicular Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 08/01/2005;23(22).

28. DL H, RB M, A E, WY T, VR G, JS J. Doxorubicin, Cardiac Risk Factors, and Cardiac Toxicity in Elderly Patients With Diffuse B-cell non-Hodgkin's Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 07/01/2008;26(19).

29. S M, M R, M B, R DA, C B, C LV, et al. Risk of Severe Cardiotoxicity Following Treatment With Trastuzumab: A Meta-Analysis of Randomized and Cohort Studies of 29,000 Women With Breast Cancer. Internal and emergency medicine 2016 2016 Feb;11(1).

30. G R, G C, S G, F T, L B, G K, et al. Role of Hypertension on New Onset Congestive Heart Failure in Patients Receiving Trastuzumab Therapy for Breast Cancer. Journal of cardiovascular medicine (Hagerstown, Md) 2014 2014 Feb;15(2).

31. Hoorn EJ, Walsh SB, McCormick JA, Zietse R, Unwin RJ, Ellison DH. Pathogenesis of calcineurin inhibitor–induced hypertension. J Nephrol 2012 May-Jun;25(3):269-75.

32. D K, J T, G J, M E. Cyclosporine Therapy After Cardiac Transplantation Causes Hypertension and Renal Vasoconstriction Without Sympathetic Activation. Circulation 1993 1993 Sep;88(3).

33. M L. Interaction of Cyclosporine A and the Renin-Angiotensin System; New Perspectives. Current drug metabolism 2002 2002 Feb;3(1).

34. Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S. Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma. J Cell Mol Med 2014 Jun;18(6):947-61.

35. JP L, JJ M, SA F, JF SM, P S, RZ O, et al. A Retrospective Analysis of 3954 Patients in Phase 2/3 Trials of Bortezomib for the Treatment of Multiple Myeloma: Towards Providing a Benchmark for the Cardiac Safety Profile of Proteasome Inhibition in Multiple Myeloma. British journal of haematology 2017 2017 Aug;178(4).

36. A C, D H. Case Series Discussion of Cardiac and Vascular Events Following Carfilzomib Treatment: Possible Mechanism, Screening, and Monitoring. BMC cancer 2014 12/04/2014;14.

37. HJ T, W W, JM K, JW L. Baroreflex Failure: A Neglected Type of Secondary Hypertension. The Netherlands journal of medicine 2004 2004 May;62(5).

38. A L, E G, A B, M L, S A, Y S, et al. The Effect of Head and Neck Radiotherapy on Blood Pressure and Orthostatic Hypotension in Patients With Head and Neck Tumors. American journal of hypertension 2018 01/12/2018;31(2).

39. LR M, EJ C, KK N, KY K, Y C, Y Y, et al. Cardiovascular Risk Factors in Adult Survivors of Pediatric Cancer--A Report From the Childhood Cancer Survivor Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2010 2010 Jan;19(1).

40. F M, M B. Glucocorticoid-dependent Hypertension. The Journal of steroid biochemistry and molecular biology 1992 1992 Oct;43(5).

41. B W, G M, W S, E AR, M A, M B, et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. European heart journal 2018 09/01/2018;39(33).

42. S L, R C, N Q, R P, R C. Age-specific Relevance of Usual Blood Pressure to Vascular Mortality: A Meta-Analysis of Individual Data for One Million Adults in 61 Prospective Studies. Lancet (London, England) 2002 12/14/2002;360(9349).

43. AR D, J S, DM B, HA L, E S. High Blood-Pressure: A Risk Factor for Cancer Mortality? Lancet (London, England) 1975 05/10/1975;1(7915).

44. PK W, RM C, WS A, DE C, KJ C, C DH, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension (Dallas, Tex : 1979) 2018 2018 Jun;71(6).

45. M A, A C, S O. Home Blood-Pressure Monitoring in Patients Receiving Sunitinib. The New England journal of medicine 2008 01/03/2008;358(1).

46. ML M, GL B, HR B, HX C, JB D, WJ E, et al. Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. Journal of the National Cancer Institute 2010 05/05/2010;102(9).

47. Humphreys BD, Atkins MB. Rapid Development of Hypertension by Sorafenib: Toxicity or Target? Clin Cancer Res 2009 Oct 1;15(19):5947-9.

48. M J, RR T. Chemotherapy Agents and Hypertension: A Focus on Angiogenesis Blockade. Current hypertension reports 2007 2007 Aug;9(4).

49. BI R, DP C, DR L, I C, S H, ME G, et al. Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. Journal of the National Cancer Institute 2011 05/04/2011;103(9).

50. Kruzliak P, Kovacova G, Pechanova O. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension. *Angiogenesis* 2013:289-95.

51. IN D, ET Y. Vascular Complications of Selected Cancer Therapies. Nature clinical practice Cardiovascular medicine 2008 2008 Dec;5(12).

52. DC D, AF L, FA G, JD H, KR H, DH J. Acute Vascular Ischemic Events After Cisplatin-Based Combination Chemotherapy for Germ-Cell Tumors of the Testis. Annals of internal medicine 1986 1986 Jul;105(1).

53. S D, R S, R C, S F, G C. Regulation of Sodium Transporters in the Kidney During Cyclosporine Treatment. Journal of nephrology 2010 Nov-Dec 2010;23 Suppl 16.

54. V R, B P, D C, X Z, S W. Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis. American journal of hypertension 2010 2010 May;23(5).

55. X Z, K S, S W. Risk of Hypertension and Renal Dysfunction With an Angiogenesis Inhibitor Sunitinib: Systematic Review and Meta-Analysis. Acta oncologica (Stockholm, Sweden) 2009 2009;48(1).

56. WX Q, F L, YJ S, LN T, AN H, Y Y, et al. Incidence and Risk of Hypertension With Pazopanib in Patients With Cancer: A Meta-Analysis. Cancer chemotherapy and pharmacology 2013 2013 Feb;71(2).

57. T F, A L, MD G. Risk of Hypertension in Cancer Patients Treated With Sorafenib: An Updated Systematic Review and Meta-Analysis. Journal of human hypertension 2013 2013 Oct;27(10).

58. WX Q, Z S, LN T, Y Y. Risk of Hypertension in Cancer Patients Treated With Aflibercept: A Systematic Review and Meta-Analysis. Clinical drug investigation 2014 2014 Apr;34(4).

59. WX Q, AN H, Z S, Y Y. Incidence and Risk of Hypertension With a Novel Multi-Targeted Kinase Inhibitor Axitinib in Cancer Patients: A Systematic Review and Meta-Analysis. British journal of clinical pharmacology 2013 2013 Sep;76(3).

60. WX Q, Z S, F L, YJ S, DL M, LN T, et al. Incidence and Risk of Hypertension With Vandetanib in Cancer Patients: A Systematic Review and Meta-Analysis of Clinical Trials. British journal of clinical pharmacology 2013 2013 Apr;75(4).

61. Z W, J X, W N, G H, J T, X G. Risk of Hypertension With Regorafenib in Cancer Patients: A Systematic Review and Meta-Analysis. European journal of clinical pharmacology 2014 2014 Feb;70(2).